ROLE OF THE HYSTONE DEACETYLASE INHIBITOR GIVINOSTAT (ITF2357) IN TREATMENT OF CRLF2 REARRANGED ACUTE LYMPHOBLASTIC LEUKEMIA

被引：0
|
作者：
Savino, A. M. [1 ]
Palmi, C. [1 ]
Fazio, G. [1 ]
Bardini, M. [1 ]
Rizzo, F. [1 ]
Cazzaniga, V. [1 ]
Bugarin, C. [1 ]
Fossati, G. [2 ]
Biondi, A. [1 ]
Cazzaniga, G. [1 ]
机构：
[1] Univ Milano Bicocca, Tettamanti Res Ctr, Pediatr Dept, San Gerardo Hosp, Monza, Italy
[2] Italfarmaco SPA Cinisello Balsamo, Cinisello Balsamo, Italy
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P112
引用
收藏
页码：5 / 6
页数：2
相关论文
共 50 条
  • [1] Role of the Histone Deacetylase Inhibitor Givinostat (ITF2357) in Treatment of CRLF2 Rearranged Acute Lymphoblastic Leukemia
    Savino, Angela Maria
    Sarno, Jolanda
    Trentin, Luca
    Vieri, Margherita
    Fazio, Grazia
    Bardini, Michela
    Bugarin, Cristina
    Fossati, Gianluca
    Davis, Kara L.
    Gaipa, Giuseppe
    Meyer, Lueder Hinrich
    Nolan, Garry P.
    Biondi, Andrea
    Kronnie, Geertruy Te
    Palmi, Chiara
    Cazzaniga, Giovanni
    BLOOD, 2015, 126 (23)
  • [2] THE HISTONE DEACETYLASE INHIBITOR GIVINOSTAT (ITF2357) HAS A POTENT ANTI-TUMOR ACTIVITY AGAINST CRLF2 REARRANGED LEUKEMIA
    Savino, A. M.
    Sarno, J.
    Trentin, L.
    Vieri, M.
    Fazio, G.
    Bardini, M.
    Bugarin, C.
    Fossati, G.
    Davis, K.
    Gaipa, G.
    Meyer, L.
    Nolan, G.
    Biondi, A.
    te Kronnie, T.
    Palmi, C.
    Cazzaniga, G.
    HAEMATOLOGICA, 2016, 101 : 198 - 198
  • [3] Synergistic drug interactions of the histone deacetylase inhibitor givinostat (ITF2357) in CRLF2-rearranged pediatric B-cell precursor acute lymphoblastic leukemia identified by high-throughput drug screening
    Oikonomou, Athanasios
    Watrin, Titus
    Valsecchi, Luigia
    Scharov, Katerina
    Savino, Angela Maria
    Schliehe-Diecks, Julian
    Bardini, Michela
    Fazio, Grazia
    Bresolin, Silvia
    Biondi, Andrea
    Borkhardt, Arndt
    Bhatia, Sanil
    Cazzaniga, Giovanni
    Palmi, Chiara
    HELIYON, 2024, 10 (13)
  • [4] The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL
    A M Savino
    J Sarno
    L Trentin
    M Vieri
    G Fazio
    M Bardini
    C Bugarin
    G Fossati
    K L Davis
    G Gaipa
    S Izraeli
    L H Meyer
    G P Nolan
    A Biondi
    G Te Kronnie
    C Palmi
    G Cazzaniga
    Leukemia, 2017, 31 : 2365 - 2375
  • [5] The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL
    Savino, A. M.
    Sarno, J.
    Trentin, L.
    Vieri, M.
    Fazio, G.
    Bardini, M.
    Bugarin, C.
    Fossati, G.
    Davis, K. L.
    Gaipa, G.
    Izraeli, S.
    Meyer, L. H.
    Nolan, G. P.
    Biondi, A.
    Kronnie, G. Te
    Palmi, C.
    Cazzaniga, G.
    LEUKEMIA, 2017, 31 (11) : 2365 - 2375
  • [6] Chemosensitization and radiosensitization effects of glioblastoma cells by the histone deacetylase inhibitor, givinostat (ITF2357) in glioblastoma cell models
    Gravina, G. L.
    Leoni, F.
    Benedetti, E.
    Delle Monache, S.
    Mancini, A.
    Angelucci, A.
    Di Cesare, E.
    Cimini, A. M.
    Porro, G.
    Festuccia, C.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S211 - S211
  • [7] Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma
    Francesco Marampon
    Flavio Leoni
    Andrea Mancini
    Ilaria Pietrantoni
    Silvia Codenotti
    Ferella Letizia
    Francesca Megiorni
    Giuliana Porro
    Elisabetta Galbiati
    Pietro Pozzi
    Paolo Mascagni
    Alfredo Budillon
    Roberto Maggio
    Vincenzo Tombolini
    Alessandro Fanzani
    Giovanni Luca Gravina
    Claudio Festuccia
    Journal of Cancer Research and Clinical Oncology, 2019, 145 : 393 - 409
  • [8] Pharmacokinetics, Safety and Inducible Cytokine Responses during a Phase 1 Trial of the Oral Histone Deacetylase Inhibitor ITF2357 (Givinostat)
    Furlan, Antonio
    Monzani, Valmen
    Reznikov, Leonid L.
    Leoni, Flavio
    Fossati, Gianluca
    Modena, Daniela
    Mascagni, Paolo
    Dinarello, Charles A.
    MOLECULAR MEDICINE, 2011, 17 (5-6) : 353 - 362
  • [9] Potent cytotoxicity against multiple myeloma and acute myeloid leukemia cells by a new histone deacetylase inhibitor ITF2357
    Rambaldi, A
    Mici, C
    Cuppini, L
    Domenghini, M
    Borleri, GM
    Barbui, AM
    Leoni, F
    Mascagni, P
    Salvi, A
    Golay, J
    Introna, M
    BLOOD, 2005, 106 (11) : 939A - 939A
  • [10] Pharmacokinetics, Safety and Inducible Cytokine Responses during a Phase 1 Trial of the Oral Histone Deacetylase Inhibitor ITF2357 (Givinostat)
    Antonio Furlan
    Valmen Monzani
    Leonid L Reznikov
    Flavio Leoni
    Gianluca Fossati
    Daniela Modena
    Paolo Mascagni
    Charles A Dinarello
    Molecular Medicine, 2011, 17 : 353 - 362
12345